Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$971,145Cash on Hand
0.5mo Cash Runway
Follow BSEM by emailGet an email when BSEM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BSEM, unsubscribe in one click. Privacy
📣 What BSEM Says Is Next
first quarter of 2027 · “Finalizing a cost reduction plan expected to reduce annualized cash operating expenses by approximately $10 to $12 million compared with the current run rate, with the full benefit beginning in the first quarter of 2027 Third Quarter 2026 Financial Results Net revenue was $7.6 million, compared to $7.9 million in the second quarter of 2026 and $10.5 million in the third quarter of 2025.”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Q3 2026 net revenue was $7.6 million versus $7.9 million in Q2 2026, with hospital revenue up to $6.8 million. GAAP net loss was $11.4 million and cash fell to $1.0 million. Full-year 2026 revenue guidance was raised to $28 million to $29 million. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 13, 2026 ·
Financing Registers resale of up to 2,224,270 shares by selling stockholders, including shares and warrants from a September 2026 private placement at $4.08 per share with Common Warrants exercisable at $3.83. The company receives no proceeds from resales, only from warrant exercises for cash. Form 424B3 · SEC filing
Sep 30, 2026 ·
Financing Sold 735,296 shares at $4.08 per share with Series A and Series B warrants at a $3.83 exercise price in a private placement for approximately $3.0 million gross, before fees. The deal closed September 30, 2026. Form 8-K · SEC filing · Press release
Sep 29, 2026 ·
Financing BioStem filed a prospectus for resale of up to 12,050,000 shares to Roth Principal Investments under a $40,000,000 committed equity facility over up to 36 months, with the company controlling sales. Form 424B3 · SEC filing
Sep 18, 2026 ·
Financing Entered a $40 million committed equity facility with Roth Principal Investments, letting the company sell common stock at its discretion once a resale registration statement is effective. Purchases are priced at VWAP less 3.0%, with a $1.00 threshold price. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Financing BioStem filed Prospectus Supplement No. 1 to update its prospectus for the resale of up to 3,571,429 common shares, attaching its Form 10-Q for the quarter ended June 30, 2026. Cash and equivalents were $6,962,492 at June 30, 2026, down from $29,549,018 at December 31, 2025. Form 424B3 · SEC filing
Aug 13, 2026 ·
Financing BioStem is registering for resale up to 3,571,429 shares held by a selling stockholder, including 746,269 shares already issued under a May 21, 2026 Securities Purchase Agreement and up to 2,825,160 shares issuable through anti-dilution adjustments at a $0.70 floor price. The company will not receive proceeds. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2026 · N/A · Results Expected · Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC Registry primary completion date, not a results date
Dec 2025 · N/A · Results Expected · A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC Registry primary completion date, not a results date
Nov 2025 · N/A · Results Expected · Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
BSEM holds $971,145 in cash and short-term investments (as of Sep 30, 2026) and burns about $5.6M/quarter from operations,
an estimated runway of 0.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:38 · Moderate
Cash runway 0 months +40
S-1 registration (Oct 2026) +8
Raised after last reported balance sheet (Sep 2026) -10
Share count 17,849,471 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BSEM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BSEM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.